Takeda Pharmaceutical (NYSE:TAK) Stock Rating Upgraded by Wall Street Zen

Takeda Pharmaceutical (NYSE:TAK) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “strong-buy” rating in a research report issued on Saturday.

Several other equities research analysts have also commented on TAK. Weiss Ratings reiterated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research note on Monday, December 29th. Morgan Stanley assumed coverage on Takeda Pharmaceutical in a research report on Tuesday, January 13th. They set an “overweight” rating on the stock. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Takeda Pharmaceutical Price Performance

Shares of NYSE TAK opened at $17.21 on Friday. The stock’s 50-day simple moving average is $15.41 and its 200-day simple moving average is $14.81. The firm has a market capitalization of $54.76 billion, a PE ratio of 71.71 and a beta of 0.03. Takeda Pharmaceutical has a fifty-two week low of $12.99 and a fifty-two week high of $17.25. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.76 and a current ratio of 1.37.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Thursday, October 30th. The company reported $0.44 EPS for the quarter, meeting the consensus estimate of $0.44. Takeda Pharmaceutical had a net margin of 2.58% and a return on equity of 10.73%. The company had revenue of $7.30 billion for the quarter, compared to analyst estimates of $8.01 billion. As a group, equities research analysts forecast that Takeda Pharmaceutical will post 1.64 EPS for the current fiscal year.

Institutional Trading of Takeda Pharmaceutical

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Private Trust Co. NA grew its stake in shares of Takeda Pharmaceutical by 84.7% in the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after purchasing an additional 783 shares during the last quarter. Twin Peaks Wealth Advisors LLC acquired a new stake in shares of Takeda Pharmaceutical during the second quarter worth $28,000. Evelyn Partners Investment Management LLP grew its position in Takeda Pharmaceutical by 163.4% in the 2nd quarter. Evelyn Partners Investment Management LLP now owns 2,515 shares of the company’s stock valued at $39,000 after buying an additional 1,560 shares during the last quarter. True Wealth Design LLC increased its stake in Takeda Pharmaceutical by 1,262.3% in the 3rd quarter. True Wealth Design LLC now owns 2,711 shares of the company’s stock valued at $40,000 after buying an additional 2,512 shares during the period. Finally, NewSquare Capital LLC raised its position in Takeda Pharmaceutical by 182.4% during the 2nd quarter. NewSquare Capital LLC now owns 3,451 shares of the company’s stock worth $53,000 after buying an additional 2,229 shares during the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Key Takeda Pharmaceutical News

Here are the key news stories impacting Takeda Pharmaceutical this week:

• Positive Sentiment: Takeda raised FY‑2025 revenue guidance to $29.4 billion and issued EPS guidance of 3.160, above consensus revenue expectations — a clear near‑term positive for top‑line visibility and investor sentiment.
• Positive Sentiment: Q3 results beat expectations: EPS $0.95 vs. $0.55 consensus; management cited cost discipline, FX tailwinds and narrowing gap between Growth & Launch products and VYVANSE generic erosion—management is tightening OPEX and raising confidence in the full‑year outlook. Takeda Reports Third-Quarter FY2025 Results
• Neutral Sentiment: CEO Christophe Weber discussed succession planning and avoiding a ‘lame duck’ exit — governance and leadership continuity themes that reduce execution risk but are longer‑term in impact. Takeda’s Christophe Weber on avoiding a ‘lame duck’ succession
• Neutral Sentiment: Earnings‑call and transcript detail product performance, launch timing and cost actions — useful for modeling but not an immediate catalyst. Takeda Q3 FY2025 Earnings Call Transcript
• Negative Sentiment: Analyst downgrade from Buy to Hold after TAK hit 52‑week highs — valuation noted as less compelling and the lack of a clear Entyvio successor reduces near‑term upside; this can pressure sentiment and limit multiple expansion. Takeda Tests New Highs, But Struggles To Find Entyvio Successor
• Negative Sentiment: Legal exposure: an adverse jury outcome in an Actos-related case and active litigation motions (including efforts to move a Louisiana suit) represent potential liabilities and headline risk that can weigh on the stock. Takeda and Eli Lilly fall foul of jury in Actos Pharma company wants La. suit over stomach acid meds moved

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.